Eurydiki Michalis

1.5k citations

24 papers · 858 indexed · h-index 13

Co-authors: Meletios Α. Dimopoulos Efstathios Kastritis Evangelos Terpos Eirini Katodritou Anastasia Pouli Konstantinos Zervas Zafiris Kartasis Sosana Delimpasi
Topics: Multiple Myeloma Research and Treatments (14 papers)Amyloidosis: Diagnosis, Treatment, Outcomes (8 papers)Lymphoma Diagnosis and Treatment (6 papers)
Cited by: Hematology Genetics Oncology
Journals: Blood Annals of Oncology International Journal of Cancer
Partner nations: Greece France Italy

In The Last Decade

Eurydiki Michalis

24 papers receiving 842 citations

Peers

Countries citing papers authored by Eurydiki Michalis

Since Specialization

Citations

This map shows the geographic impact of Eurydiki Michalis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eurydiki Michalis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eurydiki Michalis more than expected).

Fields of papers citing papers by Eurydiki Michalis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eurydiki Michalis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eurydiki Michalis. The network helps show where Eurydiki Michalis may publish in the future.

Co-authorship network of co-authors of Eurydiki Michalis

This figure shows the co-authorship network connecting the top 25 collaborators of Eurydiki Michalis. A scholar is included among the top collaborators of Eurydiki Michalis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eurydiki Michalis. Eurydiki Michalis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A very rare case of extranodal B-cell non-Hodgkin lymphoma presenting with adrenal and heart involvement 2022 ·Leukemia Research Reports ·Labrini Papanastasiou,(unknown),(unknown),Anastasia Dimitriadi,(unknown),(unknown),(unknown),(unknown),Theodoros Marinakis,Theodora Kounadi,(unknown),Eurydiki Michalis	2
2	BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years 2016 ·Blood ·Maria Gavriatopoulou,Ramón García‐Sánz,Efstathios Kastritis,Pierre Morel,(unknown),Eurydiki Michalis,Zafiris Kartasis,Xavier Leleu,Giovanni Palladini,Alessandra Tedeschi,Dimitra Gika,Giampaolo Merlini,Pieter Sonneveld,Meletios Α. Dimopoulos	53
3	Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients 2014 ·Blood ·Athanasios Zomas,Evangelos Terpos,Eirini Katodritou,Argiris Symeonidis,Sosana Delimpasi,Anastasia Pouli,Theodoros P. Vassilakopoulos,Eurydiki Michalis,Stavroula Giannouli,Zafiris Kartasis,Anna Christoforidou,(unknown),Eleftheria Hatzimichael,Dimitra Gika,(unknown),Maria Papaioannou,Marie‐Christine Kyrtsonis,Kostas Konstantopoulos,Meletios Α. Dimopoulos,Efstathios Kastritis	2
4	Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents 2013 ·Annals of Oncology ·Meletios Α. Dimopoulos,Sosana Delimpasi,Eirini Katodritou,Amalia Vassou,Maria‐Christina Kyrtsonis,Panagiotis Repousis,Zafiris Kartasis,Agapi Parcharidou,Michalis Michael,Eurydiki Michalis,Dimitra Gika,Argiris Symeonidis,Anastasia Pouli,Kostas Konstantopoulos,Evangelos Terpos,Efstathios Kastritis	109
5	The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD‐EPI‐CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD‐EPI‐CysC equations? 2013 ·European Journal Of Haematology ·Evangelos Terpos,Dimitrios Christoulas,Efstathios Kastritis,Eirini Katodritou,Anastasia Pouli,Eurydiki Michalis,Ioannis Papassotiriou,Meletios Α. Dimopoulos,(unknown)	35
6	The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group 2013 ·American Journal of Hematology ·Evangelos Terpos,Dimitrios Christoulas,Efstathios Kastritis,Eirini Katodritou,Αθανάσιος Παπαθεοδώρου,Anastasia Pouli,Marie‐Christine Kyrtsonis,Eurydiki Michalis,(unknown),Μαρία Γκοτζαμανίδου,Efstathios Koulieris,Maria Gavriatopoulou,Konstantinos Zervas,Meletios Α. Dimopoulos,(unknown)	30
7	Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN) 2013 ·Blood ·Meletios Α. Dimopoulos,Ramón García‐Sánz,Maria Gavriatopoulou,Pierre Morel,(unknown),Eurydiki Michalis,Zafiris Kartasis,Xavier Leleu,Giovanni Palladini,Alessandra Tedeschi,Dimitra Gika,Giampaolo Merlini,Efstathios Kastritis,Pieter Sonneveld	135
8	Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study 2012 ·Blood ·Meletios Α. Dimopoulos,Μαρία Ρούσσου,Efstathios Kastritis,(unknown),Marie‐Christine Kyrtsonis,Argiris Symeonidis,Panagiotis Repoussis,Eurydiki Michalis,Sosana Delimpasi,(unknown),Panagiotis Tsirigotis,Amalia Vassou,Elina Vervessou,Eirini Katodritou,Maria Gavriatopoulou,Dimitra Gika,Evangelos Terpos,Konstantinos Zervas	17
9	A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis 2012 ·Blood ·Efstathios Kastritis,Evangelos Terpos,Μαρία Ρούσσου,Maria Gavriatopoulou,Constantinos Pamboukas,Ioannis Boletis,(unknown),Theofanis Apostolou,Nikitas Nikitas,(unknown),Eurydiki Michalis,Sossana Delimpasi,Meletios Α. Dimopoulos	74
10	Significant Improvement of the Survival of Patients with Multiple Myeloma Presenting with Severe Renal Impairment After the Introduction of Novel Agents 2012 ·Blood ·Meletios Α. Dimopoulos,Sosana Delimpasi,Eirini Katodritou,Eleftheria Hatzimichael,Marie‐Christine Kyrtsonis,Panagiotis Repousis,Zafiris Kartasis,Agapi Parcharidou,Michalis Michael,Eurydiki Michalis,Dimitra Gika,Argiris Symeonidis,Konstantinos Zervas,Evangelos Terpos,Efstathios Kastritis	1
11	The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients’ renal function 2011 ·Annals of Oncology ·Meletios Α. Dimopoulos,Efstathios Kastritis,Eurydiki Michalis,Costas Tsatalas,Michalis Michael,Anastasia Pouli,Zafiris Kartasis,Sosana Delimpasi,Dimitra Gika,Athanasios Zomas,Μαρία Ρούσσου,(unknown),Agapi Parcharidou,Konstantinos Zervas,Evangelos Terpos	19
12	Circulating angiopoietin‐1 to angiopoietin‐2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents 2011 ·International Journal of Cancer ·Evangelos Terpos,Konstantinos Anargyrou,Eirini Katodritou,Efstathios Kastritis,Αθανάσιος Παπαθεοδώρου,Dimitrios Christoulas,Anastasia Pouli,Eurydiki Michalis,Sosana Delimpasi,Μαρία Γκοτζαμανίδου,Nikitas Nikitas,(unknown),Dimitrios Margaritis,Konstantinos Tsionos,Ekaterini Stefanoudaki,John Meletis,Konstantinos Zervas,Meletios Α. Dimopoulos,(unknown)	29
13	Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post‐bortezomib monotherapy 2011 ·International Journal of Cancer ·Evangelos Terpos,Dimitrios Christoulas,Eirini Katodritou,Cornelia Bratengeier,Μαρία Γκοτζαμανίδου,Eurydiki Michalis,Sosana Delimpasi,Anastasia Pouli,John Meletis,Efstathios Kastritis,Konstantinos Zervas,Meletios Α. Dimopoulos	135
14	High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents 2010 ·European Journal Of Haematology ·Evangelos Terpos,Eirini Katodritou,Μαρία Ρούσσου,Anastasia Pouli,Eurydiki Michalis,Sosana Delimpasi,Agapi Parcharidou,Zafiris Kartasis,Athanasios Zomas,Argiris Symeonidis,Nora‐Athina Viniou,Nikolaos Anagnostopoulos,Theofanis Economopoulos,Konstantinos Zervas,Meletios Α. Dimopoulos,(unknown)	102
15	Long Term Follow up of the Combination of Bortezomib with Dexamethasone as Initial Treatment for AL Amyloidosis 2010 ·Blood ·Efstathios Kastritis,Μαρία Ρούσσου,Magdalini Migkou,Maria Gavriatopoulou,Constantinos Pamboukas,(unknown),(unknown),Eurydiki Michalis,(unknown),(unknown),(unknown),(unknown),Evangelos Terpos,Meletios Α. Dimopoulos	2
16	Primary Therapy of Waldenstrom's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network 2010 ·Blood ·Meletios Α. Dimopoulos,Ramón García‐Sánz,Maria Gavriatopoulou,Pierre Morel,Marie‐Christine Kyrtsonis,Eirini Katodritou,Eurydiki Michalis,Zafiris Kartasis,Xavier Leleu,Giovanni Palladini,Alessandra Tedeschi,Dimitra Gika,Evangelos Terpos,Giampaolo Merlini,Efstathios Kastritis,Pieter Sonneveld	2
17	Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration 2009 ·Haematologica ·Evangelos Terpos,Eirini Katodritou,(unknown),Efstathios Kastritis,D. Christoulas,Anastasia Pouli,Eurydiki Michalis,(unknown),Konstantinos Anargyrou,Konstantinos Tsionos,Meletios Α. Dimopoulos,Konstantinos Zervas	56
18	Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Long Term Follow-up Analysis of a Phase II Study. 2009 ·Blood ·Meletios Α. Dimopoulos,(unknown),Marie‐Christine Kyrtsonis,Argiris Symeonidis,(unknown),Eurydiki Michalis,Sosana Delimpasi,Costas Tsatalas,Panagiotis Tsirigotis,Amalia Vassou,Elina Vervessou,Eirini Katodritou,Maria Gavriatopoulou,Nikolaos Anagnostopoulos,Dimitra Gika,Evangelos Terpos,Konstantinos Zervas	1
19	High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma. 2009 ·Blood ·Evangelos Terpos,Dimitrios Christoulas,Eirini Katodritou,Cornelia Bratengeier,(unknown),(unknown),Gerhard Hawa,(unknown),Magdalini Migkou,Maria Gavriatopoulou,Eurydiki Michalis,Anastasia Pouli,Efstathios Kastritis,Konstantinos Zervas,Meletios Α. Dimopoulos	7
20	Treatment of patients with myelodysplastic syndrome with amifostine 2001 ·Leukemia Research ·Athanasios Galanopoulos,(unknown),(unknown),Eurydiki Michalis,Vassiliki Grigoraki,(unknown),(unknown),Anastasia Tasiopoulou,Nikolaos Anagnostopoulos	7

About Eurydiki Michalis

Eurydiki Michalis is a scholar working on Hematology, Genetics and Oncology, having authored 24 papers that have together received 858 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (14 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (8 papers) and Lymphoma Diagnosis and Treatment (6 papers). The work is most often cited by research in Hematology (516 citations), Genetics (284 citations) and Oncology (341 citations). Eurydiki Michalis has collaborated with scholars based in Greece, France and Italy. Frequent co-authors include Meletios Α. Dimopoulos, Efstathios Kastritis, Evangelos Terpos, Eirini Katodritou, Anastasia Pouli, Konstantinos Zervas, Zafiris Kartasis, Sosana Delimpasi, Dimitra Gika and Maria Gavriatopoulou. Their work appears in journals such as Blood, Annals of Oncology and International Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact